Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of neramexane in congenital idiopathic and acquired nystagmus
2007-007663-25Phase 2Terminated
- Sponsor
- Merz
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neramexane in congenital idiopathic nystagmus (CIN) and Acquired nystagmus, sponsored by Merz. Primary endpoints: Long-term safety and tolerability and Permanence of visual acuity improvement. Started Oct 2008; status: terminated.
02
Drugs
neramexane
03
Conditions
congenital idiopathic nystagmus (CIN)Acquired nystagmus
Beyond the preview
Go deeper on 2007-007663-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007663-25.